Search research articles
Contact Us
Filters
Showing results (441-450 of 456) with videos related to
Page
of 46
Sort By:
Cell
|
February 1, 2024
SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion
Giuseppe Leuzzi, Alessandro Vasciaveo, Angelo Taglialatela, et al.
Immunity
|
August 7, 2024
The cytokine Meteorin-like inhibits anti-tumor CD8<sup>+</sup> T cell responses by disrupting mitochondrial function
Christopher M Jackson, Ayush Pant, Wikum Dinalankara, et al.
The New England Journal of Medicine
|
June 5, 2012
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
BMC Systems Biology
|
November 7, 2015
A multi-omic analysis of human naïve CD4+ T cells
Christopher J Mitchell, Derese Getnet, Min-Sik Kim, et al.
Cancer Discovery
|
December 9, 2024
Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Lisa N Chesner, Fanny Polesso, Julie N Graff, et al.
Nature Medicine
|
August 15, 2022
Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results
Christine D Palmer, Amy R Rappaport, Matthew J Davis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 5, 2015
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
S Gillessen, A Omlin, G Attard, et al.
The Lancet. Oncology
|
June 28, 2024
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study
Mohamad E Allaf, Se-Eun Kim, Viraj Master, et al.
European Urology
|
January 30, 2023
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study
Noah M Hahn, Michael A O'Donnell, Jason A Efstathiou, et al.
The Journal of Clinical Investigation
|
September 5, 2018
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
Daniel Nava Rodrigues, Pasquale Rescigno, David Liu, et al.
Page
of 46
Search research articles
Search
Showing results (441-450 of 456) with videos related to
Sort By:
Page
of 46
Cell
|
February 1, 2024
SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion
Giuseppe Leuzzi, Alessandro Vasciaveo, Angelo Taglialatela, et al.
Immunity
|
August 7, 2024
The cytokine Meteorin-like inhibits anti-tumor CD8<sup>+</sup> T cell responses by disrupting mitochondrial function
Christopher M Jackson, Ayush Pant, Wikum Dinalankara, et al.
The New England Journal of Medicine
|
June 5, 2012
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
BMC Systems Biology
|
November 7, 2015
A multi-omic analysis of human naïve CD4+ T cells
Christopher J Mitchell, Derese Getnet, Min-Sik Kim, et al.
Cancer Discovery
|
December 9, 2024
Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Lisa N Chesner, Fanny Polesso, Julie N Graff, et al.
Nature Medicine
|
August 15, 2022
Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results
Christine D Palmer, Amy R Rappaport, Matthew J Davis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 5, 2015
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
S Gillessen, A Omlin, G Attard, et al.
The Lancet. Oncology
|
June 28, 2024
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study
Mohamad E Allaf, Se-Eun Kim, Viraj Master, et al.
European Urology
|
January 30, 2023
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study
Noah M Hahn, Michael A O'Donnell, Jason A Efstathiou, et al.
The Journal of Clinical Investigation
|
September 5, 2018
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
Daniel Nava Rodrigues, Pasquale Rescigno, David Liu, et al.
Page
of 46